Next Gen Immuno-Oncology Congress MarketsandMarkets

June 21-22, 2018

Philadelphia - USA

37+

Speakers

200+

Attendees

7+

Sessions

The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors

Tag Line
The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors.
Tag Line
Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
Tag Line
With more than 35+ speakers at the congress, they will focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in celluar and viral therapies, vaccines development and personalized immunotherapy.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

 

Register for our 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020, write an email to [email protected]

CONFERENCE SPEAKERS

ADVISORS

Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs, Celgene

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

John Delaney

John Delaney

Executive Director, Research, Amgen

SPEAKERS

Eytan Barnea

Eytan Barnea

Founder and Chief Scientist, BioIncept LLC

Ellen Pure

Ellen Pure

Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania

Terry Fisher

Terry Fisher

Director, Translational Science and Bioanalytical, Vaccinex

Judi Wardwell-Swanson

Judi Wardwell-Swanson

Senior Application Scientist, Insphero

Pirouz Daftarian

Pirouz Daftarian

Senior Manager, Applications for Immunooncology and Vaccines , JSR Micro Life Sciences and MBL International

Raj Chavali

Raj Chavali

Senior Director, Caris Lifesciences

Joost Oppenheim

Joost Oppenheim

Head, Cellular Immunology, NIH

Christophe Queva

Christophe Queva

Chief Scientific Officer, Oncorus

Ashok Shrivastava

Ashok Shrivastava

CEO, Cure Pharmaceuticals

Mark Gardner

Mark Gardner

CEO, OmniSeq

Patrick Hanley

Patrick Hanley

Director, GMP for Immunotherapy, Assistant Professor, Children’s National Medical Centre

Frank Walsh

Frank Walsh

CEO, Ossianix Inc.

Mithun Khattar

Mithun Khattar

Immuno-Oncology Lead, Takeda Oncology

Lata Jayaraman

Lata Jayaraman

Head, Tumor Immunotherapy, Seres Therapeutics

Gregory Alberts

Gregory Alberts

Global Subject Matter Expert, Lonza Pharma Bioscience Solutions

Mark Paris

Mark Paris

Associate Director, Translational Applications, Mitra Biotech

Holly Koblish

Holly Koblish

Director, Pharmacology, ncyte

Papia Chakraborty

Papia Chakraborty

Senior Scientist, Head, Immuno-Oncology, Medgenome

Pramod Srivastava

Pramod Srivastava

Director of Cancer Center, The University of Connecticut School of Medicine

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

John Delaney

John Delaney

Executive Director, Research, Amgen

Ildiko Csiki

Ildiko Csiki

Vice President, Clinical Development Immuno- Oncology, Inovio

Ezio Bonvini

Ezio Bonvini

Senior Vice President, CSO, MacroGenics

Stephen Schoenberger

Stephen Schoenberger

Professor, Center for Cancer Immunotherapy, La Jolla University

Andrew Allen

Andrew Allen

CEO, Gritstone Oncology

Wei Zhou

Wei Zhou

Senior Research Scientist, The Jackson Laboratory

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs, Celgene

Daniel Powell

Daniel Powell

Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania

Daniel Levey

Daniel Levey

Senior Director Vaccine Research, Agenus

Wendy Clemens

Wendy Clemens

Vice President, Clinical Development, Nektar Therapeutics

Natalie Russi

Natalie Russi

Scientific Project Manager, Nebion

Lisa McNeil

Lisa McNeil

Director, Translational Medicine, Genocea

Wayne Godfrey

Wayne Godfrey

Senior Director, Clinical Development, Kite Pharma

Liang Deng

Liang Deng

Associate Member, Attending Physician, Memorial Sloan Kettering Cancer Centre

Christopher Bunker

Christopher Bunker

Vice President, Business Development, ACD-Bio-Biotechne

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Philadelphia - USA

PAST EVENT GALLERY